Patents Assigned to King Pharmaceuticals Reseach and Development, Inc.
  • Use of adenosine A3 receptor antagonists to inhibit tumor growth
    Patent number: 6326390
    Abstract: Tumor growth and metastasis can be inhibited by administration of adenosine A1 and/or A3 antagonists, preferably A3 antagonists, to a patient. The antagonists can be, and preferably are, administered in combination with other anti-tumor agents, such as anti-angiogenic agents (including adenosine A2a antagonists) and/or cytotoxic agents. Because the cytotoxic agents attack the tumor cells themselves, and the anti-angiogenic agents prevent the growth of vasculature which would otherwise support the growth of the tumor cells.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: December 4, 2001
    Assignee: King Pharmaceuticals Reseach and Development, Inc.
    Inventors: Edward Leung, Pier Giovanni Baraldi, Pier Andrea Borea, Shih-Fong Chen